MedPath

Consideration on the relation between the removal efficiency of levetiracetam and the clinical presentation by the difference in the dialysis treatment conditions

Not Applicable
Conditions
Epilepsy
Registration Number
JPRN-UMIN000042042
Lead Sponsor
Social medical corporation Kawashimakai Kawashima Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
5
Inclusion Criteria

Not provided

Exclusion Criteria

The present dialysis treatment condition is a patient besides Pre-dilution On-line HDF A sleeping pill and a Antipsychotic taking medication regularly The patient who can't get consent in study participation The patient who judged that a doctor was improper in study participation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
REBECHIRASETAMU blood level From change in dialysis method, 4 weeks later
Secondary Outcome Measures
NameTimeMethod
Drowsiness by VAS and the score of the appetite From change in dialysis method, 4 weeks later
© Copyright 2025. All Rights Reserved by MedPath